MedPath
HSA Approval

SEDILIX-DM LINCTUS

SIN07865P

SEDILIX-DM LINCTUS

SEDILIX-DM LINCTUS

October 6, 1994

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

ELIXIR

ORAL

Medical Information

R05DA20

combinations

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

DEXTROMETHORPHAN HBr

15 mg/5 ml

Dextromethorphan

PROMETHAZINE HCl

3.125 mg/5 ml

Promethazine

PSEUDOEPHEDRINE HCl

30 mg/5 ml

Pseudoephedrine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SEDILIX-DM LINCTUS - HSA Approval | MedPath